Dare Bioscience, Inc.

DARE Healthcare Biotechnology

Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024. In the quarter to June 2026, revenue grew 984.4%, EPS grew 55.6% and free cash flow fell 30.2%, each against the same quarter a year earlier.

0.72 0.02 −2.70%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
4/9
Altman Z
−8.92
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— 4 4 —

+8 more TTM periods

ROE
165.29% 272.28% 845.52% (2,543.18%)
ROA
(62.16%) (51.76%) (49.10%) (71.56%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(928.44%) (604.34%) (271.40%) (320.73%)
Average Days of Receivables
121.95 216.92 203.05 (2,360.03)
Free Cash Flow per Share
(0.78) (0.68) (0.92) (0.53)
Free Cash Flow
(11.60) (9.94) (10.27) (6.77)
Other line items

Show all line items

Columns are period end dates